Management of autoimmune bullous diseases: pharmacology and therapeutics.
Bullous diseases are associated with high morbidity and mortality. They result from autoimmune response to one or more components of the basement membrane or desmosomes. Management consists of treating the immunologic basis of the disease, treating the inflammatory process involved in lesion formation, and providing supportive care both locally and systemically. Therapeutic agents are chosen based on their known pharmacologic properties and evidence of effectiveness derived from observations and studies. Learning objectives At the completion of this learning activity, participants should be able to understand the pharmacology of drugs used in the treatment of bullous diseases, the principles of therapy for various such diseases, and a practical approach to the management of these diseases.
Mutasim
Diya F
DF
Department of Dermatology, University of Cincinnati, College of Medicine, OH 45267-0592, USA. diya.mutasim@uc.edu
D001327:Autoimmune Diseases / Q000628:therapy*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D016756:Immunoglobulins, Intravenous; D010778:Photochemotherapy; D010956:Plasmapheresis; D012872:Skin Diseases, Vesiculobullous / Q000276:immunology* / Q000628:therapy*
D003879:Dermatologic Agents; D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous